Verastem (VSTM) said Wednesday the FDA granted Fast Track designation to its experimental drug VS-7375 for patients with KRAS G12D-mutated advanced or metastatic non-small cell lung cancer.
The company is evaluating the oral therapy in its ongoing TARGET-D 101 study, with early data expected later this year.
Verastem has also launched the registration-directed Phase 2 TARGET-D 202 trial in previously treated lung cancer patients.
VS-7375 had previously received FDA Fast Track designation for KRAS G12D-mutated pancreatic cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments